Gomez M, Sampson J, Whittemore V, eds: The tuberous sclerosis complex. 1999, Oxford University Press: Oxford, England, Third
Google Scholar
Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med. 2006, 355 (13): 1345-56. 10.1056/NEJMra055323.
Article
PubMed
CAS
Google Scholar
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ: Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs. Am J Hum Genet. 2001, 68 (1): 64-80. 10.1086/316951.
Article
PubMed
CAS
Google Scholar
Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, Kwiatkowski DJ: Association between a High-Expressing Interferon-gamma Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. Am J Hum Genet. 2002, 71 (4): 750-758. 10.1086/342718.
Article
PubMed
Google Scholar
Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES: Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998, 160 (1): 141-5. 10.1016/S0022-5347(01)63072-6.
Article
PubMed
CAS
Google Scholar
Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP: Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol. 2007, 36 (4): 398-408. 10.1165/rcmb.2006-0372TR.
Article
PubMed
CAS
Google Scholar
Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000, 97 (11): 6085-90. 10.1073/pnas.97.11.6085.
Article
PubMed
CAS
Google Scholar
Consortium ECTS: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993, 75 (7): 1305-15.
Article
Google Scholar
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Ouweland van den A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997, 277 (5327): 805-8. 10.1126/science.277.5327.805.
Article
PubMed
CAS
Google Scholar
Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001, 15 (11): 1383-92. 10.1101/gad.901101.
Article
PubMed
CAS
Google Scholar
Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 2001, 105 (3): 357-68. 10.1016/S0092-8674(01)00333-6.
Article
PubMed
CAS
Google Scholar
Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell. 2006, 124 (3): 471-84. 10.1016/j.cell.2006.01.016.
Article
PubMed
CAS
Google Scholar
Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008, 27 (41): 5497-510. 10.1038/onc.2008.245.
Article
PubMed
CAS
Google Scholar
Chiang GG, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007, 13 (10): 433-42. 10.1016/j.molmed.2007.08.001.
Article
PubMed
CAS
Google Scholar
Findlay GM, Harrington LS, Lamb RF: TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?. Curr Opin Genet Dev. 2005, 15 (1): 69-76. 10.1016/j.gde.2004.11.002.
Article
PubMed
CAS
Google Scholar
Huang J, Manning BD: The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008, 412 (2): 179-90. 10.1042/BJ20080281.
Article
PubMed
CAS
Google Scholar
Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & Development. 2003, 17 (15): 1829-34.
Article
CAS
Google Scholar
Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H: Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007, 9 (2): 88-100. 10.1097/GIM.0b013e31803068c7.
Article
PubMed
CAS
Google Scholar
Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, Ouweland van den A: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005, 13 (6): 731-41. 10.1038/sj.ejhg.5201402.
Article
PubMed
CAS
Google Scholar
Messina MP, Rauktys A, Lee L, Dabora SL: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol. 2007, 7: 14-10.1186/1471-2210-7-14.
Article
PubMed
Google Scholar
Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer. 2005, 42 (3): 213-27. 10.1002/gcc.20118.
Article
PubMed
CAS
Google Scholar
El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ: Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 2003, 361 (9366): 1348-9. 10.1016/S0140-6736(03)13044-9.
Article
PubMed
CAS
Google Scholar
Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 2004, 63 (12): 1236-42.
Article
PubMed
CAS
Google Scholar
Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet. 1996, 59 (2): 400-6.
PubMed
CAS
Google Scholar
Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, Klein-Szanto AJ, Kwiatkowski DJ, Yeung RS: Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol. 1997, 151 (6): 1639-47.
PubMed
CAS
Google Scholar
Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000, 19 (56): 6680-6. 10.1038/sj.onc.1204091.
Article
PubMed
CAS
Google Scholar
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, T O'Toole, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007, 356 (22): 2271-81. 10.1056/NEJMoa066838.
Article
PubMed
CAS
Google Scholar
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372 (9637): 449-56. 10.1016/S0140-6736(08)61039-9.
Article
PubMed
CAS
Google Scholar
Ikeda S, Mochizuki A, Sarker AH, Seki S: Identification of functional elements in the bidirectional promoter of the mouse Nthl1 and Tsc2 genes. Biochem Biophys Res Commun. 2000, 273 (3): 1063-8. 10.1006/bbrc.2000.3071.
Article
PubMed
CAS
Google Scholar
Kenerson H, Dundon TA, Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005, 57 (1): 67-75. 10.1203/01.PDR.0000147727.78571.07.
Article
PubMed
CAS
Google Scholar
Lee L, Sudentas P, Dabora SL: Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer. 2006, 45 (10): 933-44. 10.1002/gcc.20357.
Article
PubMed
Google Scholar
Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006, 59 (3): 490-8. 10.1002/ana.20784.
Article
PubMed
CAS
Google Scholar
Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 200-3. 10.1056/NEJMc072500.
Article
PubMed
CAS
Google Scholar
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 140-51. 10.1056/NEJMoa063564.
Article
PubMed
CAS
Google Scholar
Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K: Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene. 2006, 25 (48): 6361-72. 10.1038/sj.onc.1209882.
Article
PubMed
CAS
Google Scholar
Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE: Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001, 97 (5): 1211-8. 10.1182/blood.V97.5.1211.
Article
PubMed
CAS
Google Scholar
Iiboshi Y, Papst PJ, Hunger SP, Terada N: L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun. 1999, 260 (2): 534-9. 10.1006/bbrc.1999.0920.
Article
PubMed
CAS
Google Scholar
Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG: Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006, 281 (42): 31222-33. 10.1074/jbc.M604511200.
Article
PubMed
CAS
Google Scholar
Arbiser JL, Brat D, Hunter S, J D'Armiento, Henske EP, Arbiser ZK, Bai X, Goldberg G, Cohen C, Weiss SW: Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol. 2002, 46 (3): 376-80. 10.1067/mjd.2002.120530.
Article
PubMed
Google Scholar
Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003, 4 (2): 147-58. 10.1016/S1535-6108(03)00187-9.
Article
PubMed
CAS
Google Scholar
Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y: Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006, 4 (3): 143-52. 10.1089/lrb.2006.4.143.
Article
PubMed
CAS
Google Scholar
Young LR, Inoue Y, McCormack FX: Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 199-200. 10.1056/NEJMc0707517.
Article
PubMed
CAS
Google Scholar
Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J: Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009, 135 (5): 1293-300. 10.1378/chest.08-1160.
Article
PubMed
CAS
Google Scholar
Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407: 597-612. 10.1016/S0076-6879(05)07047-3.
Article
PubMed
CAS
Google Scholar
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64 (19): 7099-109. 10.1158/0008-5472.CAN-04-1443.
Article
PubMed
CAS
Google Scholar
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 125-34. 10.1056/NEJMoa060655.
Article
PubMed
CAS
Google Scholar
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006, 24 (26): 4293-300. 10.1200/JCO.2005.01.3441.
Article
PubMed
CAS
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 115-24. 10.1056/NEJMoa065044.
Article
PubMed
CAS
Google Scholar
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368 (9544): 1329-38. 10.1016/S0140-6736(06)69446-4.
Article
PubMed
CAS
Google Scholar
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357 (26): 2666-76. 10.1056/NEJMoa072113.
Article
PubMed
CAS
Google Scholar
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-50. 10.1056/NEJMoa061884.
Article
PubMed
CAS
Google Scholar
Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009, 72 (14): 1217-22. 10.1212/01.wnl.0000345668.03039.90.
Article
PubMed
CAS
Google Scholar
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25 (12): 1539-44. 10.1200/JCO.2006.09.6305.
Article
PubMed
CAS
Google Scholar
Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004, 7 (4): 335-45. 10.1007/s10456-004-8272-2.
Article
PubMed
CAS
Google Scholar
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003, 349 (5): 427-34. 10.1056/NEJMoa021491.
Article
PubMed
CAS
Google Scholar
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007, 370 (9605): 2103-11. 10.1016/S0140-6736(07)61904-7.
Article
PubMed
Google Scholar
Jiang X, Yeung RS: Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Cancer Res. 2006, 66 (10): 5258-69. 10.1158/0008-5472.CAN-05-4510.
Article
PubMed
CAS
Google Scholar
Mujagic H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE: Effects of vincristine on cell survival, cell cycle progression, mitotic accumulation in asynchronously growing Sarcoma 180 cells. Cancer Res. 1983, 43 (8): 3591-7.
PubMed
CAS
Google Scholar
Himes RH, Kersey RN, Heller-Bettinger I, Samson FE: Action of the vinca alkaloids vincristine, vinblastine, desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976, 36 (10): 3798-802.
PubMed
CAS
Google Scholar
Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ: TSC2+/- mice develop tumors in multiple sites which express gelsolin and are influenced by genetic background. J Clin Invest. 1999, 104 (6): 687-95. 10.1172/JCI7319.
Article
PubMed
CAS
Google Scholar
Lee N, Woodrum C, Nobil A, Rauktys A, Messina MP, Dabora SL: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 2009, 9: 8-10.1186/1471-2210-9-8.
Article
PubMed
Google Scholar
de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol. 2007, 9 (4): 412-23. 10.1215/15228517-2007-024.
Article
PubMed
CAS
Google Scholar
Huynh H, Teo CC, Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther. 2007, 6 (11): 2959-66. 10.1158/1535-7163.MCT-07-0237.
Article
PubMed
CAS
Google Scholar
Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004, 103 (10): 3905-14. 10.1182/blood-2003-08-2911.
Article
PubMed
CAS
Google Scholar
Rauktys A, Lee N, Lee L, Dabora SL: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol. 2008, 8 (1): 1-10.1186/1471-5945-8-1.
Article
PubMed
Google Scholar
Doetschman T: Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol. 2009, 530: 423-33. full_text.
Article
PubMed
CAS
Google Scholar
Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ: Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008, 28 (21): 5422-32. 10.1523/JNEUROSCI.0955-08.2008.
Article
PubMed
CAS
Google Scholar
Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ: Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008, 14 (8): 843-8. 10.1038/nm1788.
Article
PubMed
CAS
Google Scholar
Zeng LH, Xu L, Gutmann DH, Wong M: Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008, 63 (4): 444-53. 10.1002/ana.21331.
Article
PubMed
CAS
Google Scholar
Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP: Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA. 2009, 106 (8): 2635-40. 10.1073/pnas.0810790106.
Article
PubMed
CAS
Google Scholar
Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D: Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer. 2009, 8: 38-10.1186/1476-4598-8-38.
Article
PubMed
Google Scholar
El-Hashemite N, Walker V, Kwiatkowski DJ: Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res. 2005, 65 (6): 2474-81. 10.1158/0008-5472.CAN-04-3840.
Article
PubMed
CAS
Google Scholar
Lenci I, Angelico M, Tisone G, Orlacchio A, Palmieri G, Pinci M, Bombardieri R, Curatolo P: Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment. J Hepatol. 2008, 48 (6): 1026-9. 10.1016/j.jhep.2008.01.036.
Article
PubMed
Google Scholar
Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ: Renal and liver tumors in Tsc2+/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther. 2009, 8 (7): 1799-807. 10.1158/1535-7163.MCT-09-0055.
Article
PubMed
CAS
Google Scholar